Preimplantation Genetic Testing Market Share Driven by Advancements in Reproductive Genetics, Assisted Reproductive Technologies, and Precision Diagnostics | Valuates Reports

Preimplantation Genetic Testing Market Size
The global market for Preimplantation Genetic Testing was valued at US$ 397 million in the year 2024 and is projected to reach a revised size of US$ 586 million by 2031, growing at a CAGR of 5.8% during the forecast period.

View sample report
https://reports.valuates.com/request/sample/QYRE-Othe-0H192/preimplantation_genetic_testing_market

The Preimplantation Genetic Testing Market continues to expand as fertility specialists, reproductive healthcare providers, and genetic laboratories increasingly integrate advanced genomic technologies into assisted reproductive treatment. Growing awareness of inherited genetic disorders, increasing utilization of in vitro fertilization (IVF), and improvements in molecular diagnostic technologies are among the primary factors supporting market growth. Healthcare providers are increasingly adopting genetic testing prior to embryo transfer to improve embryo selection, reduce the likelihood of transmitting inherited genetic conditions, and support informed clinical decision-making. Market trends are also being influenced by continuous advancements in next-generation sequencing (NGS), polymerase chain reaction (PCR), chromosomal analysis, and bioinformatics platforms that enable greater analytical accuracy and improved laboratory workflows. Expanding maternal age in many countries, rising demand for personalized reproductive care, and increasing acceptance of fertility treatments are contributing to sustained market size growth. In addition, investments in reproductive medicine, genetic research, laboratory automation, and quality assurance continue to strengthen diagnostic capabilities while improving testing efficiency. Regulatory oversight, evolving clinical practice guidelines, and ongoing innovation in reproductive genomics continue to shape the competitive landscape. Together, these factors support continued market growth, expanding market share across reproductive healthcare services, and a favorable long-term market forecast.

The market is segmented into Preimplantation Genetic Screening (PGS) and Preimplantation Genetic Diagnosis (PGD), both of which play distinct roles in embryo evaluation during assisted reproduction. Preimplantation Genetic Screening, now more commonly referred to in clinical practice as preimplantation genetic testing for aneuploidy (PGT-A), currently accounts for the largest market share because it is widely used to evaluate chromosomal abnormalities in embryos during IVF procedures. Its adoption has increased as fertility clinics seek to improve embryo selection and support successful pregnancy outcomes for a broad range of patients. Preimplantation Genetic Diagnosis, now commonly aligned with preimplantation genetic testing for monogenic disorders (PGT-M), remains an essential segment for couples with a known risk of transmitting specific inherited genetic diseases. It enables targeted analysis of embryos for well-characterized genetic conditions before implantation. Both testing approaches continue to benefit from advancements in sequencing technologies, improved analytical sensitivity, and greater laboratory standardization. Publicly available industry evidence supports continued growth across both testing categories, although definitive global rankings regarding the fastest-growing segment vary depending on regional clinical practice and regulatory environments. Market trends increasingly favor comprehensive genomic analysis, integrated laboratory workflows, and enhanced diagnostic accuracy, supporting sustained market growth while strengthening market share and reinforcing the long-term market forecast.

From an application perspective, maternity centers and fertility clinics represent the largest segment and account for the highest market share within the Preimplantation Genetic Testing Market. These specialized reproductive healthcare facilities perform the majority of IVF procedures and routinely collaborate with genetic laboratories to evaluate embryos before implantation. The increasing number of fertility treatments worldwide, combined with growing patient awareness of reproductive genetics, continues to strengthen demand within this segment. Hospitals, diagnostic laboratories, and service providers also represent a significant application category by offering specialized genetic testing, molecular diagnostics, and reproductive medicine services that support fertility specialists and patients. Their expanding laboratory capabilities, investment in advanced sequencing technologies, and multidisciplinary clinical expertise contribute to continued market growth. Research laboratories and academic institutes play an important role in advancing reproductive genetics through scientific research, technology development, validation studies, and clinical innovation. Market trends indicate increasing collaboration among fertility centers, diagnostic laboratories, biotechnology companies, and academic institutions to improve testing methodologies, laboratory efficiency, and clinical outcomes. Continued expansion of assisted reproductive technologies, broader access to fertility services, and increasing integration of genomic medicine into reproductive healthcare are expected to sustain market growth across all application segments while supporting future market share development.

The competitive landscape includes several globally recognized life sciences companies, diagnostic technology providers, and specialized reproductive genetics organizations that continue to advance innovation within the Preimplantation Genetic Testing Market. Illumina remains one of the leading technology providers through its widely adopted next-generation sequencing platforms that support comprehensive genomic analysis across reproductive diagnostics. Thermo Fisher Scientific offers an extensive portfolio of molecular biology instruments, sequencing technologies, and laboratory solutions used in genetic testing workflows. Agilent Technologies contributes advanced genomic analysis platforms, reagents, and laboratory technologies that support high-quality molecular diagnostics. PerkinElmer provides genetic screening solutions and laboratory technologies serving reproductive health and clinical diagnostics. CooperSurgical has established a strong presence in fertility care by offering reproductive technologies, embryo assessment solutions, and laboratory products designed for assisted reproduction. Abbott Laboratories participates in molecular diagnostics through technologies supporting clinical laboratory testing and healthcare services. Natera is recognized for its expertise in genetic testing and reproductive health diagnostics, while Rubicon Genomics, Oxford Gene Technology, Yikon Genomics, Scigene, Beijing Genomics Institute (BGI), Good Start Genetics, Invicta Genetics, Combimatrix, Genea Limited, and Progenesis contribute specialized expertise across reproductive genomics, sequencing technologies, laboratory services, and genetic analysis. These prominent market participants continue strengthening the industry through research and development, laboratory automation, strategic collaborations, technology innovation, geographic expansion, and continuous improvement of genomic testing platforms. Their ongoing investments in precision diagnostics and reproductive medicine continue to shape competitive dynamics while supporting market growth and expanding market share.

North America currently holds the largest market share in the Preimplantation Genetic Testing Market, supported by advanced fertility treatment infrastructure, high adoption of assisted reproductive technologies, strong investment in genomic medicine, and the presence of numerous leading biotechnology and diagnostics companies. The United States represents the largest regional market due to extensive availability of fertility clinics, sophisticated molecular diagnostic laboratories, and continued innovation in reproductive healthcare. Europe also maintains a substantial market share, supported by established healthcare systems, expanding reproductive medicine programs, and ongoing advancements in genetic diagnostics across Germany, France, the United Kingdom, Italy, and the Nordic countries. Asia-Pacific is expected to experience robust market growth as countries including China, Japan, South Korea, India, and Australia continue investing in fertility care, precision medicine, and genomic research while improving access to advanced reproductive technologies. Latin America and the Middle East & Africa are also witnessing gradual expansion as fertility awareness increases, healthcare infrastructure develops, and specialized genetic testing services become more widely available. Looking ahead, the market forecast remains favorable as next-generation sequencing continues to evolve, artificial intelligence supports genomic data interpretation, laboratory automation enhances testing efficiency, and reproductive medicine becomes increasingly personalized. Continued innovation in molecular diagnostics, expanding clinical research, stronger regulatory frameworks, and growing collaboration between fertility specialists and genomic technology providers are expected to shape future market trends, strengthen market growth, expand market size, and support sustained market share development across the global Preimplantation Genetic Testing Market.

Segment by Type

• Preimplantation Genetic Screening
• Preimplantation Genetic Diagnosis

Segment by Application

• Maternity Centers & Fertility Clinics
• Hospitals, Diagnostic Labs, and Service Providers
• Research Laboratories & Academic Institutes

By Company

Illumina, Thermo Fisher, Agilent Technologies, Perkinelmer, Coopersurgical, Abbott Laboratories, Natera, Rubicon Genomics, Oxford Gene Technology, Yikon Genomics, Scigene, Beijing Genomics Institute, Good Start Genetics, Invicta Genetics, Combimatrix, Genea Limited, Progenesis

View full report
https://reports.valuates.com/market-reports/QYRE-Othe-0H192/preimplantation-genetic-testing

Valuates,
4th Floor,
Balaraj's Arcade,
Whitefield Main road,
Bangalore 560066,

Valuates offers an extensive collection of market research reports that helps companies to take intelligent strategical decisions based on current and forecasted Market trends.

This release was published on openPR.